Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection (Q43976039)

28 November 2017

Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection (English)

1 reference

28 November 2017

1 reference

1 reference

1 reference

4

Elizabeth M Brunt

1 reference

28 November 2017

Hari H Diwakaran

1

1 reference

28 November 2017

Alex S Befeler

series ordinal

2

1 reference

28 November 2017

Robert S Britton

series ordinal

3

1 reference

28 November 2017

Bruce R Bacon

series ordinal

5

1 reference

28 November 2017

1 May 2002

1 reference

28 November 2017

Journal of Hepatology

1 reference

28 November 2017

36

1 reference

28 November 2017

5

1 reference

28 November 2017

687-691

1 reference

Molecular medicine and hemochromatosis: at the crossroads

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Measurements of iron status in patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Iron in liver diseases other than hemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: diagnostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Lipid peroxidation and associated hepatic organelle dysfunction in iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Hepatic injury in chronic iron overload. Role of lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Metal-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Iron and chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Response to interferon alpha therapy is influenced by the iron content of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Failure to respond to interferon-alpha 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Hemochromatosis: diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Iron and liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900018-1

7 January 2021

10.1016/S0168-8278(02)00018-1

Identifiers

DOI

1 reference

28 November 2017

1 reference